Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection

Öz Discovery of novel and broad-acting immunomodulators is of critical importance for the prevention and treatment of disorders occurring due to overexuberant immune responseincluding SARS-CoV-2 triggered cytokine storm leading to lung pathology and mortality during the ongoing viral pandemic. Mesenchymal stem/stromal cells (MSCs), highly regarded for their regenerative capacities, also possessesremarkable immunoregulatory functions affecting all types of innate and adaptive immune cells. Owing to that, MSCs have been heavily investigated in clinic for the treatment of autoimmune and inflammatory diseases along with transplant rejection. Extensive research in the last decaderevealed that MSCs carry out most of their functions through paracrine factors which are soluble mediators and extracellular vesicles (EVs). EVs, including exosomes and microvesicles, are an efficient way of intercellular communication due to their unique ability to carry biological messages such as transcription factors, growth factors, cytokines, mRNAs and miRNAs over long distances. EVs originate through direct budding of the cell membrane or the endosomal secretion pathway and they consist of the cytosolic and membrane components of their parent cell. Therefore, they are able to mimic the characteristics of the parent cell, affecting the target cells upon binding or internalization. EVs secreted by MSCs are emerging as a cell-free alternative to MSC-based therapies. MSC EVs are being tested in preclinical and clinical settings where they exhibit exceptional immunosuppressivecapacity. They regulate the migration, proliferation, activation and polarization of various immune cells, promoting a tolerogenic immune response while inhibiting inflammatory response. Being as effective immunomodulators as their parent cells, MSC EVs are also preferable over MSC-based therapies due to their lower risk of immunogenicity, tumorigenicity and overall superior safety. In this review, we present the outcomes of preclinical and clinical studies utilizing MSC EVs as therapeutic agents for the treatment of a wide variety of immunological disorders.

Kaynakça

Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007

Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002

Arthur A, 2008, STEM CELLS, V26, P1787, DOI 10.1634/stemcells.2007-0979

Bai LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04559-y

Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006

Bian SY, 2014, J MOL MED, V92, P387, DOI 10.1007/s00109-013-1110-5

Brandau S, 2010, J LEUKOCYTE BIOL, V88, P1005, DOI 10.1189/jlb.0410207

Brown JM, 2011, CLIN EXP ALLERGY, V41, P526, DOI 10.1111/j.1365-2222.2010.03685.x

Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886

Chatterjee D, 2014, BLOOD, V123, P594, DOI 10.1182/blood-2013-09-524827

Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886

Cho DI, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.135

Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353

Ciccocioppo R, 2011, GUT, V60, P788, DOI 10.1136/gut.2010.214841

Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657

Cosenza S, 2018, THERANOSTICS, V8, P1399, DOI 10.7150/thno.21072

CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5

Crop MJ, 2010, CLIN EXP IMMUNOL, V162, P474, DOI 10.1111/j.1365-2249.2010.04256.x

Deng YA, 2014, STEM CELLS DEV, V23, P2080, DOI 10.1089/scd.2013.0559

Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838

Ding DC, 2011, CELL TRANSPLANT, V20, P5, DOI 10.3727/096368910X

Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905

El Omar R, 2014, TISSUE ENG PART B-RE, V20, P523, DOI [10.1089/ten.teb.2013.0664, 10.1089/ten.TEB.2013.0664]

Figliuzzi Marina, 2014, World J Stem Cells, V6, P163, DOI 10.4252/wjsc.v6.i2.163

Forbes GM, 2014, CLIN GASTROENTEROL H, V12, P64, DOI 10.1016/j.cgh.2013.06.021

Franquesa M, 2015, STEM CELLS, V33, P880, DOI 10.1002/stem.1881

FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x

Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood-2004-09-3696

Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12

Hoffmann M., 2020, BIORXIV, DOI [10.1101/2020.01.31.929042., DOI 10.1101/2020.01.31.929042]

Jiang DS, 2016, STEM CELLS, V34, P2393, DOI 10.1002/stem.2417

Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029

Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248

Kim HS, 2017, STEM CELLS, V35, P248, DOI 10.1002/stem.2401

Kim HS, 2015, STEM CELLS, V33, P1254, DOI 10.1002/stem.1913

Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41

Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003

LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X

Lee C, 2012, CIRCULATION, V126, P2601, DOI 10.1161/CIRCULATIONAHA.112.114173

Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228

Li TF, 2013, STEM CELLS DEV, V22, P845, DOI 10.1089/scd.2012.0395

Li XY, 2014, INT J MOL MED, V34, P695, DOI 10.3892/ijmm.2014.1821

Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717

Liu XX, 2012, J IMMUNOL, V189, P1182, DOI 10.4049/jimmunol.1102996

Luz-Crawford P, 2016, STEM CELLS, V34, P483, DOI 10.1002/stem.2254

Luz-Crawford P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt216

Maas SLN, 2017, TRENDS CELL BIOL, V27, P172, DOI 10.1016/j.tcb.2016.11.003

Mao F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5356760

Marrazzo P, 2019, J MOL MED, V97, P437, DOI 10.1007/s00109-019-01752-6

Melief SM, 2013, STEM CELL TRANSL MED, V2, P455, DOI 10.5966/sctm.2012-0184

Minciacchi VR, 2015, SEMIN CELL DEV BIOL, V40, P41, DOI 10.1016/j.semcdb.2015.02.010

Nassar Wael, 2016, Biomater Res, V20, P21, DOI 10.1186/s40824-016-0068-0

Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905

Nojehdehi S, 2018, J CELL BIOCHEM, V119, P9433, DOI 10.1002/jcb.27260

Pan GH, 2016, ONCOTARGET, V7, P12089, DOI 10.18632/oncotarget.7725

Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143

Plumas J, 2005, LEUKEMIA, V19, P1597, DOI 10.1038/sj.leu.2403871

Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014

Schena F, 2010, ARTHRITIS RHEUM-US, V62, P2776, DOI 10.1002/art.27560

Selleri S, 2016, ONCOTARGET, V7, P30193, DOI 10.18632/oncotarget.8623

Shen B, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1240301

Shigemoto-Kuroda T, 2017, STEM CELL REP, V8, P1214, DOI 10.1016/j.stemcr.2017.04.008

Snykers S, 2009, STEM CELLS, V27, P577, DOI 10.1634/stemcells.2008-0963

Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997

Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943

Stahl PD, 2019, PHYSIOLOGY, V34, P169, DOI 10.1152/physiol.00045.2018

Su J, 2014, CELL DEATH DIFFER, V21, P388, DOI 10.1038/cdd.2013.149

Sun GD, 2018, MAT SCI ENG C-MATER, V89, P194, DOI 10.1016/j.msec.2018.04.006

Tabera S, 2008, HAEMATOL-HEMATOL J, V93, P1301, DOI 10.3324/haematol.12857

Tamura R, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0030-5

Tan JM, 2012, JAMA-J AM MED ASSOC, V307, P1169, DOI 10.1001/jama.2012.316

Teng XM, 2015, CELL PHYSIOL BIOCHEM, V37, P2415, DOI 10.1159/000438594

Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052

Wang BY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-016-0463-4

Wang DD, 2013, CELL TRANSPLANT, V22, P2267, DOI [10.3727/096368911X582769c, 10.3727/096368911X582769]

Wang L, 2016, STEM CELLS DEV, V25, P1874, DOI 10.1089/scd.2016.0107

Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088

Wiklander OPB, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav8521

Willis GR, 2018, AM J RESP CRIT CARE, V197, P104, DOI 10.1164/rccm.201705-0925OC

Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066

Yang J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140551

Yuana Y, 2013, BLOOD REV, V27, P31, DOI 10.1016/j.blre.2012.12.002

Zhang B, 2009, BLOOD, V113, P46, DOI 10.1182/blood-2008-04-154138

Zhang QZ, 2010, STEM CELLS, V28, P1856, DOI 10.1002/stem.503

Zhang W, 2004, STEM CELLS DEV, V13, P263, DOI 10.1089/154732804323099190

Zhang ZW, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002856

Zhao H, 2018, DIABETES, V67, P235, DOI 10.2337/db17-0356

Zhao K, 2015, BIOL BLOOD MARROW TR, V21, P97, DOI 10.1016/j.bbmt.2014.09.030

Zhao RCH, 2020, STEM CELLS DEV, V29, P679, DOI 10.1089/scd.2020.0071

Kaynak Göster

Bibtex @araştırma makalesi { tbtkbiology943546, journal = {Turkish Journal of Biology}, issn = {1300-0152}, eissn = {1303-6092}, address = {}, publisher = {TÜBİTAK}, year = {2020}, volume = {44}, pages = {273 - 282}, doi = {}, title = {Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection}, key = {cite}, author = {Bulut, Ozlem and Gursel, Ihsan} }
APA Bulut, O , Gursel, I . (2020). Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection . Turkish Journal of Biology , Special Issue on COVID-19 , 273-282 . Retrieved from https://dergipark.org.tr/tr/pub/tbtkbiology/issue/62502/943546
MLA Bulut, O , Gursel, I . "Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection" . Turkish Journal of Biology 44 (2020 ): 273-282 <https://dergipark.org.tr/tr/pub/tbtkbiology/issue/62502/943546>
Chicago Bulut, O , Gursel, I . "Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection". Turkish Journal of Biology 44 (2020 ): 273-282
RIS TY - JOUR T1 - Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection AU - Ozlem Bulut , Ihsan Gursel Y1 - 2020 PY - 2020 N1 - DO - T2 - Turkish Journal of Biology JF - Journal JO - JOR SP - 273 EP - 282 VL - 44 IS - SI-1 SN - 1300-0152-1303-6092 M3 - UR - Y2 - 2020 ER -
EndNote %0 Turkish Journal of Biology Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection %A Ozlem Bulut , Ihsan Gursel %T Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection %D 2020 %J Turkish Journal of Biology %P 1300-0152-1303-6092 %V 44 %N SI-1 %R %U
ISNAD Bulut, Ozlem , Gursel, Ihsan . "Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection". Turkish Journal of Biology 44 / SI-1 (Haziran 2020): 273-282 .
AMA Bulut O , Gursel I . Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection. Turkish Journal of Biology. 2020; 44(SI-1): 273-282.
Vancouver Bulut O , Gursel I . Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection. Turkish Journal of Biology. 2020; 44(SI-1): 273-282.
IEEE O. Bulut ve I. Gursel , "Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection", Turkish Journal of Biology, c. 44, sayı. SI-1, ss. 273-282, Haz. 2020

7033 2341

Arşiv
Sayıdaki Diğer Makaleler

An updated analysis of variations in SARS-CoV-2 genome

Osman Mutluhan UGUREL, Oguz ATA, Dilek TURGUT-BALİK

Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection

Ozlem BULUT, Ihsan GURSEL

SARS-CoV-2 neutralizing antibody development strategies

Bertan Koray BALCİOGLU, Melis Denizci ONCU, Hasan Umit OZTURK, Fatima YUCEL, Filiz KAYA, Muge SERHATLİ, Hivda Ulbegi POLAT, Saban TEKİN, Aylin Ozdemir BAHADİR

An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19

Murat TOPUZOGULLARİ, Tayfun ACAR, Pelin PELİT ARAYICI, Burcu UÇAR, Erennur UĞUREL, Emrah Şefik ABAMOR, Tülin ARASOĞLU, Dilek BALIK-TURGUT, Serap DERMAN

SARS-CoV-2 isolation and propagation from Turkish COVID-19 patients

Cihan TASTAN, Bulut YURTSEVER, Gozde Sir KARAKUS, Derya Dilek KANCAGİ, Sevda DEMİR, Selen ABANUZ, Utku SEYİS, Mulazim YİLDİRİM, Recai KUZAY, Omer ELİBOL, Serap ARBAK, Merve Acikel ELMAS, Selcuk BİRDOGAN, Osman Ugur SEZERMAN, Aye Sesin KOCAGOZ, Koray YALCİN, Ercument OVALİ

Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties

Erman Salih ISTİFLİ, Arzuhan Sihoglu TEPE, Cengiz SARİKURKCU, Bektas TEPE

Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target

Serdar DURDAGİ

Integration of transcriptomic profile of SARS-CoV-2 infected normal human bronchial epi-thelial cells with metabolic and protein-protein interaction networks

Hamza Umut KARAKURT, Pinar PİR

Identification of the nucleotide substitutions in 62 SARS-CoV-2 sequences from Turkey

Ayse Banu DEMİR, Domenico BENVENUTO, Hakan ABACİOGLU, Silvia ANGELETTİ, Massimo CİCCOZZİ

Potentials of plant-based substance to inhabit and probable cure for the COVID-19

Israt JAHAN, Ahmet ONAY